{"id":95911,"date":"2025-04-15T08:08:01","date_gmt":"2025-04-15T06:08:01","guid":{"rendered":"https:\/\/www.formycon.com\/?page_id=95911"},"modified":"2026-03-20T10:59:35","modified_gmt":"2026-03-20T09:59:35","slug":"fyb202-ustekinumab","status":"publish","type":"page","link":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","title":{"rendered":"FYB202 Ustekinumab"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; equal_height=&#8221;yes&#8221; gutter_size=&#8221;0&#8243; shift_y=&#8221;0&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;2&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_custom_heading text_color=&#8221;color-155072&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221;]FYB202[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;100099&#8243; text_color_type=&#8221;uncode-palette&#8221;]Ustekinumab Biosimilar[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;h3&#8243; text_weight=&#8221;300&#8243; text_height=&#8221;fontheight-357766&#8243; uncode_shortcode_id=&#8221;120383&#8243;]As a treatment option for patients with chronic inflammatory diseases, FYB202 is on the market in the US, Europe, and Canada. Further product launches are planned, including in the MENA region.[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;585328&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;134115&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_single_image media=&#8221;97782&#8243; media_width_use_pixel=&#8221;yes&#8221; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;368489&#8243; media_width_pixel=&#8221;1400&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;513525&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;134115&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_single_image media=&#8221;97782&#8243; media_lightbox=&#8221;yes&#8221; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;186804&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;762269&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;581096&#8243; back_color_type=&#8221;uncode-palette&#8221; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;917321&#8243;]<strong>Indication Area<br \/>\n<\/strong>Immunology[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;919064&#8243;]<strong>Active Ingredient Group<br \/>\n<\/strong>Immunosuppressants \/<br \/>\nInterleukin inhibitors[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;800245&#8243;]<strong>Indications of the Reference Drug<br \/>\n<\/strong>Crohn&#8217;s disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis*<strong><br \/>\n<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;132579&#8243;]<strong>Market Launch<br \/>\n<\/strong>2025<strong><br \/>\n<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;135266&#8243;]<strong>Ustekinumab Market<\/strong><br \/>\nUstekinumab is a well-established and widely used biologic drug for the treatment of chronic inflammatory diseases. Global sales of the reference drug Stelara\u00ae amounted to approximately $6 billion in 2025.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;205982&#8243; el_width=&#8221;100%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;176429&#8243;]<b>Commercialization partners:<\/b>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;105944&#8243;]<strong><img decoding=\"async\" class=\"alignnone size-full wp-image-96057\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/FK.png\" alt=\"\" width=\"153\" height=\"40\" srcset=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/FK.png 153w, https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/FK-150x40.png 150w\" sizes=\"(max-width: 153px) 100vw, 153px\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Otulfi\u00ae<br \/>\n<strong>Region:<\/strong> Key global markets[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;116936&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97807 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Teva_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Fymskina\u00ae<br \/>\n<strong>Region:<\/strong> Germany[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;181127&#8243;]<strong><img decoding=\"async\" class=\"alignnone size-full wp-image-97801\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/MSPharma_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Sitovab\u00ae<br \/>\n<strong>Region:<\/strong> MENA<\/p>\n<p><strong>\u00a0<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183068&#8243;][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;149492&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;150708&#8243;]<\/p>\n<div style=\"text-align: right;\">* The specific indication groups approved are listed in the product information<br \/>\nprovided by the EMA or FDA.<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;118803&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;97738&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;991364&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;202553&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_empty_space empty_h=&#8221;4&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;116480&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB202 Biosimilar Development[\/vc_custom_heading][vc_empty_space empty_h=&#8221;4&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;447782&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;96109&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;209157&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;801105&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_size=&#8221;h4&#8243; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;143297&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB202 Biosimilar Development[\/vc_custom_heading][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;185374&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;102763&#8243; column_width_pixel=&#8221;800&#8243;][vc_empty_space empty_h=&#8221;3&#8243; mobile_visibility=&#8221;yes&#8221;][vc_accordion typography=&#8221;yes&#8221; gutter_simple=&#8221;0&#8243; uncode_shortcode_id=&#8221;605931&#8243; el_id=&#8221;devdetails&#8221; el_class=&#8221;devdetails&#8221; active_tab=&#8221;0&#8243;][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;FYB202 (Ustekinumab) Mode of Action&#8221; tab_id=&#8221;1730916296154-2-101744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183589&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; subheading=&#8221;Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 and is used to treat various serious inflammatory diseases such as moderate to severe psoriasis. In 2016, its therapeutic range was expanded to include the treatment of Crohn&#8217;s disease and, in 2019, ulcerative colitis, both of which are chronic inflammatory bowel diseases. The drug is also used to treat psoriatic arthritis.&#8221; uncode_shortcode_id=&#8221;193206&#8243; heading_custom_size=&#8221;24px&#8221;]How does FYB202 (Ustekinumab) work?[\/vc_custom_heading][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;142771&#8243;]<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/overview\/otulfi-epar-medicine-overview_en.pdf\" target=\"_blank\" rel=\"noopener\">Further Information<\/a><\/p>\n<p>[\/vc_column_text][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Development and Commercialization Milestones&#8221; tab_id=&#8221;1730790947-1-351744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;188630&#8243;][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;243008&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Teva subsidiary Ratiopharm becomes secondary commercialization partner for FYB202\/Fymskina\u00ae in Germany<\/span>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;115752&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Commercial Launch of FYB202\/Otulfi\u00ae in Canada<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-announce-the-commercial-launch-of-fyb202-otulfi-an-approved-ustekinumab-biosimilar-in-canada\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;147568&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Commercial Launch of FYB202\/Otulfi\u00ae in the U.S. and the E.U.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb202-otulfi-ustekinumab-aauz-a-biosimilar-to-stelara-launched-in-the-united-states-and-the-european-union\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;126698&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">January 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approval in the UK<br \/>\n<\/span><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-announce-mhra-approval-for-fyb202-otulfi-ustekinumab-a-biosimilar-to-stelara\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;186359&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">January 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approval in Canada<br \/>\n<\/span><a href=\"&quot;https:\/\/www.formycon.com\/blog\/press-release\/formycon-und-fresenius-kabi-canada-erhalten-zulassung-von-health-canada-fuer-fyb202-otulfi-ustekinumab-ein-biosimilar-zu-stelara\/\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;761298&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">MS Pharma becomes commercialization partner for the MENA Region<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/ms-pharma-becomes-partner-for-the-commercialization-of-fyb202-ustekinumab-in-the-mena-region\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;170176&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">September 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB202 Approval in the U.S.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-receive-fda-approval-for-fyb202-otulfi-ustekinumab-aauz\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;155191&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">September 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB202 Approval in the E.U.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-receive-european-commission-approval-for-fyb202-otulfi-ustekinumab-for-the-treatment-of-serious-inflammatory-diseases\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;359602&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">July 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Positive CHMP opinion for the E.U. marketing authorization of FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-receive-positive-chmp-opinion-for-fyb202\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;626227&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Settlement agreement with Johnson &amp; Johnson for Europa and Canada<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-reach-settlement-agreement-for-ustekinumab-biosimilar-candidate-fyb202-in-europe-and-canada\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;467535&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">File acceptance by the U.S. Food and Drug Administration (FDA)<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/file-acceptance-fyb202\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;889067&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">September 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Acceptance of the Marketing Authorization Application by the EMA<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-announce-european-medicines-agency-acceptance-of-the-marketing-authorization-application-for-fyb202-an-ustekinumab-biosimilar-candidate\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;697909&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Settlement agreement with Johnson &amp; Johnson for FYB202 in the U.S.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb202-settlement-agreement-us\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;234419&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">April 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Successful completion of clinical development of FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-successful-results-of-phase-i-clinical-trial-for-ustekinumab-biosimilar-candidate-fyb202-and-concludes-clinical-development\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;178455&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Global commercialization partnership with Fresenius Kabi<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-conclude-global-commercialization-partnership-for-fyb202\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;213735&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Positive interim results from Phase III study<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycons-biosimilar-ustekinumab-candidate-fyb202-shows-comparable-efficacy-to-reference-product-stelara-in-phase-iii-study\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;385011&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Formycon acquires full rights of FYB202 in a transaction with ATHOS KG<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-is-acquiring-the-biosimilar-assets-fyb201-and-fyb202-and-strengthening-its-position-in-the-global-growth-market-of-biosimilars-through-long-term-partnership-with-athos-kg\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;534056&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2020<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Start of clinical Phase III Study<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-bioeq-announce-launch-of-phase-iii-study-of-fyb202-a-biosimilar-candidate-for-stelarar-ustekinumab\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;199716&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">October 2019<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Start of clinical Phase I Study<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-start-of-phase-i-clinical-trial-with-ustekinumab-biosimilar-candidate-fyb202\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;313457&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2017<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Formycon and Aristo Pharma establish joint venture for the development of FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-aristo-pharma-are-founding-a-joint-venture-for-the-development-of-fyb202-2\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;115737&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2017<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Disclosure of the reference for FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-details-of-further-pipeline-product-fyb202-is-a-biosimilar-candidate-for-stelara-ustekinumab\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Scientific Publications on FYB202&#8243; tab_id=&#8221;1730790947-2-501744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;693360&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; subheading=&#8221;Data on the comparability of the biosimilar FYB202 with the reference drug were published in several poster presentations and in a scientific article.&#8221; uncode_shortcode_id=&#8221;148917&#8243; heading_custom_size=&#8221;24px&#8221;]Preclinical ans clinical Data[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][vc_gallery el_id=&#8221;gallery-130684&#8243; type=&#8221;carousel&#8221; medias=&#8221;95994,95992,95990,96054&#8243; carousel_lg=&#8221;3&#8243; carousel_md=&#8221;2&#8243; carousel_sm=&#8221;1&#8243; gutter_size=&#8221;3&#8243; media_items=&#8221;media|custom_link|original,description,icon,caption&#8221; carousel_interval=&#8221;3000&#8243; carousel_navspeed=&#8221;400&#8243; carousel_loop=&#8221;yes&#8221; stage_padding=&#8221;0&#8243; single_overlay_opacity=&#8221;50&#8243; single_padding=&#8221;2&#8243; uncode_shortcode_id=&#8221;275767&#8243; single_link=&#8221;url:https%3A%2F%2Fwww.formycon.com%2Funternehmen%2Fkontakt%2F|title:Kontakt&#8221; items=&#8221;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&#8243;][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;762269&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;372897&#8243; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; limit_content=&#8221;&#8221; uncode_shortcode_id=&#8221;149764&#8243; css=&#8221;.vc_custom_1757693219486{padding-right: 112px !important;}&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;745787&#8243;][vc_empty_space empty_h=&#8221;2&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;999486&#8243;]<\/p>\n<div style=\"text-align: right;\">Stelara\u00ae is a registered trademark of Johnson &amp; Johnson<br \/>\nOtulfi\u00ae is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries<\/div>\n<div style=\"text-align: right;\">Fymskina\u00ae is a registered trademark of Formycon AG<\/div>\n<div style=\"text-align: right;\">Sitovab\u00ae is a registered trademark of MS Pharma<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]<\/p>\n","protected":false},"author":23,"featured_media":81334,"parent":78082,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-95911","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FYB202 Ustekinumab - Formycon AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FYB202 Ustekinumab - Formycon AG\" \/>\n<meta property=\"og:description\" content=\"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Formycon AG\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T09:59:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/\",\"url\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/\",\"name\":\"FYB202 Ustekinumab - Formycon AG\",\"isPartOf\":{\"@id\":\"https:\/\/www.formycon.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg\",\"datePublished\":\"2025-04-15T06:08:01+00:00\",\"dateModified\":\"2026-03-20T09:59:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage\",\"url\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg\",\"contentUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg\",\"width\":1600,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.formycon.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars\",\"item\":\"https:\/\/www.formycon.com\/en\/biosimilars\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FYB202 Ustekinumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.formycon.com\/en\/#website\",\"url\":\"https:\/\/www.formycon.com\/en\/\",\"name\":\"Formycon AG\",\"description\":\"Global Quality Biosimilars\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.formycon.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FYB202 Ustekinumab - Formycon AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","og_locale":"en_US","og_type":"article","og_title":"FYB202 Ustekinumab - Formycon AG","og_description":"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]","og_url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","og_site_name":"Formycon AG","article_modified_time":"2026-03-20T09:59:35+00:00","og_image":[{"width":1600,"height":800,"url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","name":"FYB202 Ustekinumab - Formycon AG","isPartOf":{"@id":"https:\/\/www.formycon.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage"},"image":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg","datePublished":"2025-04-15T06:08:01+00:00","dateModified":"2026-03-20T09:59:35+00:00","breadcrumb":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage","url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg","contentUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg","width":1600,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.formycon.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biosimilars","item":"https:\/\/www.formycon.com\/en\/biosimilars\/"},{"@type":"ListItem","position":3,"name":"FYB202 Ustekinumab"}]},{"@type":"WebSite","@id":"https:\/\/www.formycon.com\/en\/#website","url":"https:\/\/www.formycon.com\/en\/","name":"Formycon AG","description":"Global Quality Biosimilars","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.formycon.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-23 03:46:53","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/95911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/comments?post=95911"}],"version-history":[{"count":4,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/95911\/revisions"}],"predecessor-version":[{"id":99366,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/95911\/revisions\/99366"}],"up":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media\/81334"}],"wp:attachment":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media?parent=95911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}